News Release

Mallinckrodt Pharmaceuticals Data Presented at Annual Scientific Conference

June 3, 2019

On Monday, June 3, 2019 Mallinckrodt presented data at the Michael, Marcia, and Christa Parseghian Scientific Conference for Niemann-Pick Type C (NPC) Research. The conference, which runs June 1-4, is being held in Tucson, Ariz., and the presentation took place at 1:20 p.m. Pacific. The presentation is available at

  • Rationale for Mallinckrodt data presentation: The data is being presented as the conference is a unique opportunity to engage the NPC scientific and patient community and discuss the results of the VTS-270 Phase 2b/3 clinical trial, along with other data, with the patients and parents that have supported the trial. While the company has communicated that the Phase 2b/3 trial top-line results did not meet statistical significance, this was an opportunity to share additional information more broadly as Mallinckrodt assesses the next steps for the overall VTS-270 program.
  • About the Conference:  This conference is about sharing basic, translational, and clinical research towards a greater understanding and a cure for Niemann-Pick Type C disease. Attendees include scientists, patients and patient advocates. For more information visit their website.

Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reporting segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reporting segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.


Investor Relations
Daniel J. Speciale, CPA
Vice President, Investor Relations and IRO

Daniel Yunger
Kekst CNC

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. © 2019 Mallinckrodt. 6/19